Encouraging Biomarker Data Lift UniQure’s Huntington’s Disease Hopes
Results Exceeded Expectations
Hopes rise as first four evaluable patients experienced no serious adverse events, and a sustained decline in level of key Huntington’s disease protein with the novel gene therapy product.
